December 21, 2021
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
December 16, 2021
Press Release: Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi
December 15, 2021
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
December 14, 2021
Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessions
December 13, 2021
Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session
December 11, 2021
Sarclisa® (isatuximab) trial is first Phase 3 study to meet primary endpoint of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma
December 8, 2021
New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
December 6, 2021
EMA accepts regulatory submission for olipudase alfa, the first potential therapy for ASMD
December 1, 2021
Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
December 1, 2021
Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
November 18, 2021
Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline
November 12, 2021
Sanofi announces results of CHMP re-examination of the New Active Substance status for avalglucosidase alfa, a potential new standard of care for the treatment of Pompe disease
November 9, 2021
Sanofi completes acquisition of Kadmon
November 4, 2021
New data in blood cancers, hemophilia, and other hematological disorders to be presented at ASH 2021
October 28, 2021
Sanofi: Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)
October 25, 2021
Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease
October 22, 2021
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
October 20, 2021
FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
October 13, 2021
New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021 
October 12, 2021
Update from Sanofi regarding Kevzara® (sarilumab): Supply constraints anticipated until early 2022
October 7, 2021
Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations
September 30, 2021
New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis
September 28, 2021
Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate
September 28, 2021
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
September 27, 2021
New research presented at IDWeek 2021 reinforces Sanofi’s robust vaccines pipeline and commitment to advancing public health protection
September 24, 2021
Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes
September 21, 2021
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
September 19, 2021
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
September 14, 2021
Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics
September 9, 2021
Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
September 8, 2021
Sanofi to acquire Kadmon to further strengthen growth of transplant business
September 3, 2021
Dupixent® (dupilumab) efficacy and quality of life data in asthma patients across multiple age groups to be presented at 2021 ERS international congress
August 30, 2021
Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
August 6, 2021
FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease
August 5, 2021
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
August 3, 2021
Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development
July 29, 2021
Online availability of Sanofi’s half-year financial report for 2021
July 29, 2021
Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI
July 29, 2021
Sales growth accelerated - Full-year guidance raised
July 29, 2021
Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients  
July 27, 2021
Sanofi provides update on avalglucosidase alfa EU submission for patients with Pompe Disease
July 22, 2021
Sanofi continues streamlining of established products with sale of dental care brands to Septodont
July 19, 2021
US FDA approves fexinidazole as the first all-oral treatment for sleeping sickness
July 15, 2021
Conversion of Kiadis to a private limited liability company postponed until completion of statutory buy-out proceedings
July 13, 2021
Sanofi streamlines Consumer Healthcare portfolio in Latin America with divestiture of eight brands to Hypera Pharma
July 10, 2021
MenQuadfi® demonstrates superior immune response against serogroup C meningococcal disease in toddlers
July 2, 2021
Sanofi highlights scientific innovations in the field of rare blood disorders at ISTH 2021
June 29, 2021
Sanofi launches dedicated vaccines mRNA Center of Excellence
June 28, 2021
New Soliqua® data shows improved blood sugar control without weight gain versus premixed insulin
June 28, 2021
Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial
June 28, 2021
Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA
June 28, 2021
Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis
June 25, 2021
Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes
June 25, 2021
Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
June 25, 2021
Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
June 22, 2021
Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine
June 18, 2021
European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
June 11, 2021
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia  
June 11, 2021
Sanofi provides update on Aubagio® (teriflunomide) submission for children and adolescents with relapsing-remitting multiple sclerosis in the U.S.
June 7, 2021
Sanofi launches its new global employee share ownership plan
June 4, 2021
Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
June 3, 2021
Sanofi launches €3 million Planet Mobilization fund to support employees’ environmental projects
June 1, 2021
Sanofi provides update on venglustat clinical program
May 27, 2021
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
May 24, 2021
Libtayo® (cemiplimab) receives positive CHMP opinion for the treatment in Europe of two advanced cancers
May 19, 2021
Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting
May 19, 2021
Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer
May 17, 2021
Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children
May 17, 2021
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
May 12, 2021
New data to be featured at EHA 2021 Congress highlight Sanofi’s ongoing commitment to rare blood disorders
May 12, 2021
Positive Phase 3 Libtayo® (cemiplimab) results in advanced cervical cancer presented at ESMO Virtual Plenary
May 6, 2021
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
April 30, 2021
Annual General Meeting of April 30, 2021
April 29, 2021
Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer
April 28, 2021
Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
April 26, 2021
Delisting of Kiadis will be effective on 25 May 2021
April 26, 2021
Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands
April 26, 2021
Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
April 23, 2021
New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
April 19, 2021
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
April 16, 2021
Sanofi completes Kiadis acquisition
April 13, 2021
Sanofi declares the offer for Kiadis unconditional
April 9, 2021
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
April 9, 2021
Sanofi completes Kymab acquisition
April 9, 2021
Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2
April 7, 2021
Positive results from the sutimlimab pivotal trial for people with cold agglutinin disease published in New England Journal of Medicine
April 7, 2021
Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
March 31, 2021
FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
March 31, 2021
Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine
March 23, 2021
Sanofi continues streamlining of established products with sale of anti-inflammatory drugs to Fidia Farmaceutici
March 19, 2021
Availability of the Q1 2021 Memorandum for modelling purposes
March 15, 2021
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival           
March 12, 2021
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
March 4, 2021
Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
March 4, 2021
FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
March 3, 2021
Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
February 26, 2021
CHMP recommends approval of Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for the treatment of relapsed multiple myeloma
February 22, 2021
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
February 22, 2021
Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands
February 22, 2021
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
February 18, 2021
Efanesoctocog alfa granted FDA Fast Track Designation for treatment of hemophilia A
February 12, 2021
Offer Memorandum for All Outstanding Shares of Kiadis Pharma N.V.
February 12, 2021
Sanofi launches recommended cash offer for all shares in Kiadis
February 12, 2021
The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
February 9, 2021
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
February 9, 2021
New indication for Plavix® (clopidogrel) now approved in the European Union
February 5, 2021
Sanofi presents amended protocols in fitusiran clinical studies at EAHAD 2021
February 5, 2021
Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
February 5, 2021
Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
February 2, 2021
Kiadis shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi
February 2, 2021
 Data presented at WORLDSymposiumTM reinforces robust rare disease pipeline and highlights additional clinical data for investigational avalglucosidase alfa in Pompe disease
February 1, 2021
New Dupixent® (dupilumab) data showcasing improvements across four type 2 inflammatory diseases to be presented at 2021 AAAAI Annual Meeting
January 27, 2021
Sanofi to provide support to BioNTech in manufacturing their COVID-19 vaccine to help address public health needs
January 12, 2021
SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer
January 11, 2021
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L